Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 31;15(3):199-209.
doi: 10.9758/cpn.2017.15.3.199.

Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines

Hee Ryung Wang  1 , Won-Myong Bahk  1 , Jeong Seok Seo  2 , Young Sup Woo  1 , Young-Min Park  3 , Jong-Hyun Jeong  4 , Won Kim  5   6 , Se-Hoon Shim  7 , Jung Goo Lee  8   9   10 , Duk-In Jon  11 , Kyung Joon Min  12
Affiliations
Review

Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines

Hee Ryung Wang et al. Clin Psychopharmacol Neurosci. .

Abstract

In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.

Keywords: Depressive disorder; Expert consensus; Guideline; KMAP-DD 2017; Therapy.

PubMed Disclaimer

References

    1. Song HR, Bahk WM, Woo YS, Jeong JH, Kwon YJ, Seo JS, et al. Efficacy and tolerability of generic mirtazapine (Mirtax) for major depressive disorder: multicenter, open-label, uncontrolled, prospective study. Clin Psychopharmacol Neurosci. 2015;13:144–149. doi: 10.9758/cpn.2015.13.2.144. - DOI - PMC - PubMed
    1. Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2016;196:225–233. doi: 10.1016/j.jad.2016.02.042. - DOI - PubMed
    1. McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs. 2015;75:1915–1923. doi: 10.1007/s40265-015-0490-y. - DOI - PubMed
    1. Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry. 2015;48:187–199. doi: 10.1055/s-0035-1555879. - DOI - PubMed
    1. Zadka Ł, Dziwota E, Olajossy M. Levomilnacipran—a successor of milnacipran with a higher noradrenergic selectivity. Acta Pol Pharm. 2016;73:285–289. - PubMed